Clinical Trials in California

Showing 11241-11260 of 11,359 trials

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

NCT00042679

The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer. The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs. How LY900003 is distributed and broken down by your body when it is given with carboplatin and gemcitabine. Whether LY900003 affects the way gemcitabine and carboplatin are distributed and broken down by your body.

Carcinoma, Non-Small-Cell LungPulmonary NeoplasmsNeoplasms, Lung

Eli Lilly and CompanyStarted Jun 2002

Bakersfield, California, United States • Berkeley, California, United States • Torrance, California, United States +8 more locations

COMPLETEDPhase 263 miles

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

NCT00065312

The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.

Diabetes Mellitus, Non-Insulin-Dependent

Eli Lilly and Company

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Peoria, Arizona, United States +39 more locations

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

Find Trials by Condition in California

A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures

Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)

The Evaluation of OrCel for the Treatment of Venous Ulcers

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Optic Neuritis Treatment Trial (ONTT)

Longitudinal Optic Neuritis Study (LONS)

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression